Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Stoke Therapeutics, Inc. (STOK : NSDQ)

• Company Description    Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. Number of Employees: 170

• Price / Volume Information    Yesterday's Closing Price: $32.85 Daily Weekly Monthly 20 Day Moving Average: 1,015,660 shares Shares Outstanding: 59.15 (millions) Market Capitalization: $1,943.11 (millions) Beta: 1.07 52 Week High: $40.22 52 Week Low: $5.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.59% 0.24% 12 Week 3.50% 11.24% Year To Date 3.50% 12.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 45 WIGGINS AVENUE - BEDFORD,MA 01730 USA ph: 781-430-8200 fax: - ir@stoketherapeutics.com http://www.stoketherapeutics.com

• General Corporate Information    Officers Ian F. Smith - Chief Executive Officer and Director Arthur O. Tzianabos - Chairman of the Board of Directors Thomas E. Leggett - Chief Financial Officer Julie A. Smith - Director Seth L. Harrison - Director Peer Information Stoke Therapeutics, Inc. (CORR.) Stoke Therapeutics, Inc. (RSPI) Stoke Therapeutics, Inc. (CGXP) Stoke Therapeutics, Inc. (BGEN) Stoke Therapeutics, Inc. (GTBP) Stoke Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 86150R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/12/26 Share - Related Items Shares Outstanding: 59.15 Most Recent Split Date: (:1) Beta: 1.07 Market Capitalization: $1,943.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.80 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.41 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.32 Price/Cash Flow: - Price / Sales: 10.54 EPS Growth vs. Year Ago Period: -438.89% vs. Previous Quarter: -49.23% Sales Growth vs. Year Ago Period: -93.80% vs. Previous Quarter: -86.81% ROE 12/31/25 - -2.05 09/30/25 - 13.28 06/30/25 - 18.32 ROA 12/31/25 - -1.75 09/30/25 - 11.40 06/30/25 - 15.48 Current Ratio 12/31/25 - 5.28 09/30/25 - 6.53 06/30/25 - 6.98 Quick Ratio 12/31/25 - 5.28 09/30/25 - 6.53 06/30/25 - 6.98 Operating Margin 12/31/25 - -3.73 09/30/25 - 19.73 06/30/25 - 26.25 Net Margin 12/31/25 - -3.73 09/30/25 - 19.73 06/30/25 - 26.25 Pre-Tax Margin 12/31/25 - -3.73 09/30/25 - 19.73 06/30/25 - 26.90 Book Value 12/31/25 - 6.17 09/30/25 - 5.62 06/30/25 - 6.13 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©